Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | PON1 | P27169 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5439303 | 0.98 | CYP19A1 (0.31) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL5449882 | 0.94 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL5445948 | 0.88 | KCNH2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL5444906 | 0.88 | CYP11B1 (0.33) | CYP11B1CYP11B2CYP19A1PON1 | |
| Bromide SCHEMBL5445820 | 0.86 | CYP19A1 (0.30) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL12576055 | 0.84 | CYP11B1 (0.33) | CYP11B1CYP11B2CYP19A1PON1 | |
| SCHEMBL5442178 | 0.83 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL5446071 | 0.78 | KCNH2 (0.35) | — | |
| SCHEMBL12513969 | 0.75 | LMNA (0.41) | CYP19A1PON1KMT2A | |
| SCHEMBL16724702 | 0.73 | GAA (0.32) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021615-A1 | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | claimed |
| US-20070021615-A1 | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| US-20060293526-A1 | Immobilised imidazoles and ruthenium catalysts | MERK PATENT GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
| US-20060287450-A1 | Immobilizable ruthenium catalysts having n-heterocyclic carbene ligands | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2006-12-21 | — | — | US | disclosed |
| US-20060270547-A1 | N-heterocyclic carbenes that can be immobilized | MERCK PATENT GMBH (DE) | 2006-11-30 | — | — | US | disclosed |
| EP-1654265-A1 | N-HETEROCYCLIC CARBENES THAT CAN BE IMMOBILIZED | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| EP-1654064-A2 | IMMOBILISED IMIDAZOLES AND RUTHENIUM CATALYSTS | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016524-A2 | IMMOBILISED IMIDAZOLES AND RUTHENIUM CATALYSTS | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016941-A1 | N-HETEROCYCLIC CARBENES THAT CAN BE IMMOBILIZED | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287450-A1 | Immobilizable ruthenium catalysts having n-heterocyclic carbene ligands | NUDC, NSFL1C, ORC3 | CYP11B1 1072/4885CYP11B2 600/4885CYP19A1 2386/4885 |
| US-20060270547-A1 | N-heterocyclic carbenes that can be immobilized | SIRT3, B3GNT2, SIRT2 | CYP11B1 1269/4885CYP11B2 758/4885CYP19A1 1527/4885 |
| US-20070021615-A1 | Imidazolium salts that can be immobilized | IDH1, IDH3B, MIF | CYP11B1 424/4885CYP11B2 277/4885CYP19A1 2456/4885 |
| US-20060293526-A1 | Immobilised imidazoles and ruthenium catalysts | PIN4, MIF, SCO2 | CYP11B1 583/4885CYP11B2 275/4885CYP19A1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.